Exor N.V.

Koninklijke Philips has updated its long-term agreement with Exor, allowing Exor to raise its shareholding to 22% while existing governance arrangements remain unchanged. Philips shares last closed at €23.19, down 3.74% over the past month, though the three-year total shareholder return stands at 31.21%. A widely followed valuation narrative pegs fair value at €23.40, implying the stock is undervalued, while the consensus price target is €27.59. Risks include prolonged tariffs, complex China procurement, and extended hospital order cycles.

Exor N.V. has appointed Benoît Ribadeau-Dumas as Deputy Chief Executive Officer, effective 1 July 2026. Ribadeau-Dumas will continue to report to Chief Executive Officer John Elkann, who will also become Chair of Exor’s London-based investment management company, Lingotto, from the same date. Chief Operating Officer Suzanne Heywood will step down from her executive responsibilities in January 2027 to pursue opportunities outside of Exor, but will remain involved in the governance of Exor’s investee companies, including as Chair of CNH and Iveco Group and as a board member of The Economist Group and Christian Louboutin. Elkann noted that Lingotto’s assets under management have surpassed $10 billion.